Black Diamond Therapeutics, Inc. (BDTX)
1.805
-0.14
(-6.96%)
USD |
NASDAQ |
Oct 06, 16:00
1.805
0.00 (0.00%)
After-Hours: 19:59
Black Diamond Therapeutics Enterprise Value : 17.91M for Oct. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 05, 2026 | 17.91M |
| October 02, 2026 | 15.04M |
| October 01, 2026 | 14.46M |
| September 30, 2026 | 14.75M |
| September 29, 2026 | 13.89M |
| September 28, 2026 | 11.59M |
| September 25, 2026 | 14.46M |
| September 24, 2026 | 15.04M |
| September 23, 2026 | 15.61M |
| September 22, 2026 | 20.21M |
| September 21, 2026 | 18.48M |
| September 18, 2026 | 19.06M |
| September 17, 2026 | 17.34M |
| September 16, 2026 | 17.91M |
| September 15, 2026 | 19.63M |
| September 14, 2026 | 23.08M |
| September 11, 2026 | 20.21M |
| September 10, 2026 | 19.06M |
| September 09, 2026 | 27.10M |
| September 08, 2026 | 27.10M |
| September 04, 2026 | 28.25M |
| September 03, 2026 | 27.10M |
| September 02, 2026 | 29.40M |
| September 01, 2026 | 23.65M |
| August 31, 2026 | 27.10M |
| Date | Value |
|---|---|
| August 28, 2026 | 34.57M |
| August 27, 2026 | 36.87M |
| August 26, 2026 | 36.87M |
| August 25, 2026 | 35.14M |
| August 24, 2026 | 30.26M |
| August 21, 2026 | 33.42M |
| August 20, 2026 | 29.97M |
| August 19, 2026 | 32.27M |
| August 18, 2026 | 24.80M |
| August 17, 2026 | 24.23M |
| August 14, 2026 | 22.51M |
| August 13, 2026 | 22.51M |
| August 12, 2026 | 27.10M |
| August 11, 2026 | 26.53M |
| August 10, 2026 | 20.21M |
| August 07, 2026 | 18.48M |
| August 06, 2026 | 16.76M |
| August 05, 2026 | 9.293M |
| August 04, 2026 | 8.718M |
| August 03, 2026 | 6.133M |
| July 31, 2026 | 3.548M |
| July 30, 2026 | 4.984M |
| July 29, 2026 | 1.825M |
| July 28, 2026 | 7.570M |
| July 27, 2026 | 5.846M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 636.69M |
| Amgen, Inc. | 261.17B |
| BioCryst Pharmaceuticals, Inc. | 2.551B |
| Imunon, Inc. | 6.766M |
| Curis, Inc. | -3.035M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.905M |
| Total Expenses (Quarterly) | 9.905M |
| EPS Diluted (Quarterly) | -0.1727 |
| Earnings Yield | -41.26% |
| Normalized Earnings Yield | -36.26 |